Search

Search Constraints

You searched for: Author/Creator Dubinsky, M

Search Results

1. A37 EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN'S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY. (21st February 2022)

3. DOP008 Safety of adalimumab in children and adolescents with moderate-to-severe Crohn's disease: interim results of the CAPE registry. (16th January 2018)

4. DOP012 Disease demarcation in ulcerative colitis is associated with different patterns of gene expression. (16th January 2018)

6. DOP38 Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1. (21st January 2022)

7. DOP50 Effect of upadacitinib on extra-intestinal manifestations in patients with moderate to severe Crohn's disease: data from the CELEST study. (25th January 2019)

9. DOP82 Achievement of steroid-free remission in patients with moderately to severely active Crohn's Disease during treatment with risankizumab. (21st January 2022)

10. DOP87 The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn's Disease: Phase 2a APOLLO-CD Study Results. (30th January 2023)